Pan-mutant-selective PI3Kα inhibitor
Breast Cancer
AcquisitionUnder acquisition
Key Facts
About Novartis
Novartis is an innovative medicines company with over 250 years of heritage and 30 years as Novartis, dedicated to reimagining medicine to improve and extend people's lives. The company operates across four core therapeutic areas with high unmet medical needs and leverages multiple technology platforms including chemistry, biotherapeutics, xRNA, radioligand therapy, and gene and cell therapy. With a global footprint spanning 118 countries and a mission to become the most valued and trusted medicines company in the world, Novartis continues to deliver high-value medicines through technology leadership in R&D and novel access approaches.
View full company profileTherapeutic Areas
Other Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Verzenio (abemaciclib) | Eli Lilly | Approved |
| Trodelvy | Royalty Pharma | Commercial |
| Trastuzumab biosimilar (IBI306) | Innovent Biologics | Phase 3 |
| Ogivri (trastuzumab biosimilar) | Viatris | Approved |
| Trastuzumab Biosimilar | Dr. Reddy's Laboratories | Approved |
| Biosimilar Trastuzumab | Cipla | Commercial |
| Ogivri (Trastuzumab) | Biocon | Approved |
| Tamoxifen | Natco Pharma | Approved |
| ARV-027 | Arvinas | Phase 1 |
| Prognostic Genomic Tests | Eurobio Scientific | Commercial |
| Selinexor | Karyopharm Therapeutics | Clinical Trials |
| ATNM-400 | Actinium Pharmaceuticals | Preclinical |